Contemporary management of superficial bladder cancer in the United States: A pattern of care analysis

Urology

Volumn 62, Issue 6, 2003, Pages 1083-1088

  Joudi, Fadi N ^a   Smith, Brian J ^a   O'Donnell, Michael A ^a   Konety, Badrinath R ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CARCINOMA; BLADDER PRESSURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; MEDICAL PRACTICE; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SUPERFICIAL CANCER; UNITED STATES;

EID: 0345528210     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00765-9     Document Type: Article

References (12)

1. Parker S.L., Tong T., Bolden S., et al. Cancer statistics, 1997. CA Cancer J Clin. 47:1997;5-27.
2. Catalona W.J. Urothelial tumors of the urinary tract. Walsh P.C., Retik A.B., Stamey T.A., et al. Campbell's Urology. 6th ed. 1992;1094-1158 WB Saunders, Philadelphia.
3. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacilli Calmete-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 325:1991;1205-1209.
4. Smith J.R., Labasky R.F., Cockett A.T.K., et al. Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and CIS). J Urol. 162:1999;1697-1701.
5. O'Leary MP, Gee WF, Holtgrewe HL, et al: 1999 American Urological Association Gallup Survey: Changes in physician practice patterns, treatment of incontinence and bladder cancer and impact of managed care. J Urol 164: 1311-1316, 2000.
6. Bower M., Savage R., Abel P., et al. British urological survey practice 2 - renal, bladder and testis cancer . Br J Urol. 81:1998;513-517.
7. Obek C., Shelfo S., Korman H., et al. Intravesical therapy for transitional cell carcinoma of the bladder the community practice . Urology. 53:1999;82-87.
8. Catalona W., Hudson M., Gillen D., et al. Risks and benefits of repeated courses of intravesical bacillus Calmete-Guérin for superficial bladder cancer. J Urol. 137:1987;220-224.
9. Rintala E., Jauhainen K., Kaasinen E., et al. Alternating mitomycin C and bacillus Calmete-Guérin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol. 156:1996;56-60.
10. Witjes J., Caris C., Mungan N., et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmete-Guérin versus mitomycin C alone in patients with superficial bladder cancer. J Urol. 160:1998;1668-1672.
11. Malmström P-U, Wijkström H, Lundholm C, et al: 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmete-Guérin in patients with superficial bladder carcinoma. J Urol 161: 1124-1127, 1999.
12. Herr H., Sogani P. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 166:2001;1296-1299.